1346243-08-0

Basic information

• Product Name: N-(cyclopropylmethyl)-N-(3,5-dimethoxyphenyl)-3-(1H-pyrazol-4-yl)quinoxaline-6-amine
• Synonyms: N-(cyclopropylmethyl)-N-(3,5-dimethoxyphenyl)-3-(1H-pyrazol-4-yl)quinoxaline-6-amine
• CAS NO: 1346243-08-0
• Molecular Weight: 401.468
• Mol File: 1346243-08-0.mol
• Article Data: 2

Chemical Properties

• CAS DataBase Reference: N-(cyclopropylmethyl)-N-(3,5-dimethoxyphenyl)-3-(1H-pyrazol-4-yl)quinoxaline-6-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N-(cyclopropylmethyl)-N-(3,5-dimethoxyphenyl)-3-(1H-pyrazol-4-yl)quinoxaline-6-amine(1346243-08-0)
• EPA Substance Registry System: N-(cyclopropylmethyl)-N-(3,5-dimethoxyphenyl)-3-(1H-pyrazol-4-yl)quinoxaline-6-amine(1346243-08-0)

Safety Data

• Hazardous Substances Data: 1346243-08-0(Hazardous Substances Data)

Upstream product

• 1346246-09-0 N-(3,5-dimethoxyphenyl)-3-(1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl)quinoxaline-6-amine 
• 1346245-22-4 7-bromo-2-[1-(tetrahydro-2H-pyran-2-yl)-1H-pyrazol-4-yl]-quinoxaline 
• 1196-57-2 2-hydroxyquinoxaline 
• 89891-65-6 7-bromo-2-chloroquinoxaline 
• 82031-32-1 2-hydroxy-7-bromoquinoxaline 
• 1346245-21-3 C₂₈H₃₁N₅O₄ 
• 1346245-20-2 C₂₀H₂₀ClN₃O₂ 
• 1346245-12-2 C₁₆H₁₅N₃O₃ 
• 1346245-13-3 3-chloro-N-(3,5-dimethoxyphenyl)quinoxalin-6-amine 
• 552846-17-0 tert-butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole-1-carboxylate 
• 82031-32-1 7-bromo-1H-quinoxalin-2-one 
• 10272-07-8 3.5-dimethoxyaniline 

Downstream Products

• 1346243-83-1 C₂₇H₃₁N₅O₃ 
• 1346243-90-0 C₂₆H₂₇N₅O₂ 
• 1346243-88-6 C₂₅H₂₈N₆O₄S 
• 1346243-82-0 C₂₅H₂₆BrN₅O₂ 
• 1346246-43-2 C₃₁H₄₁N₅O₃Si 
• 1346243-85-3 C₃₁H₃₈N₆O₃ 
• 1346243-30-8 C₂₆H₂₉N₅O₄ 
• 1346243-86-4 C₂₅H₂₇N₅O₃ 
• 1346243-91-1 C₂₆H₃₀N₆O₂ 
• 1346244-07-2 C₂₅H₂₆FN₅O₂ 

Relevant articles and documents

Double-target inhibitor targeting FGFR (fibroblast growth factor receptor) and HDAC (histone deacetylase) as well as preparation method and application thereof, pharmaceutical composition and medicament

The invention discloses a double-target inhibitor targeting FGFR (fibroblast growth factor receptor) and HDAC (histone deacetylase) as well as a preparation method and application thereof, a pharmaceutical composition and a medicament, and belongs to the